Multiple Myeloma: Available Therapies and Causes of Drug Resistance.

Pinto, Vanessa; Bergantim, Rui; Caires, Hugo R; Seca, Hugo; Guimarães, José E; Vasconcelos, M Helena

Pinto, Vanessa; Bergantim, Rui; Caires, Hugo R; Seca, Hugo; Guimarães, José E; Vasconcelos, M Helena.

Afiliación

Pinto V; i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.
Bergantim R; Cancer Drug Resistance Group, IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, 4200-135 Porto, Portugal.
Caires HR; FCTUC-Faculty of Science and Technology of the University of Coimbra, 3030-790 Coimbra, Portugal.
Seca H; i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.
Guimarães JE; Cancer Drug Resistance Group, IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, 4200-135 Porto, Portugal.
Vasconcelos MH; Clinical Hematology, Hospital São João, 4200-319 Porto, Portugal.

Cancers (Basel) ; 12(2)2020 Feb 10.

Article en En | MEDLINE | ID: mdl-32050631

Palabras clave

drug resistance; drug response; multiple myeloma; treatment

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google